A considerable portion of the population across geographies are suffering from a wide range of infectious diseases such as influenza, tuberculosis, AIDS, and several other bacterial and viral diseases. Tuberculosis or TB is one of the leading causes of death worldwide. Currently, organizations such as the World Health Organization (WHO) and the Foundation for Innovative New Diagnostics (OTCPK:FIND) have contributed largely towards improving global awareness regarding TB, its diagnosis, and available treatment options through TB control programs such as Stop TB. According to the WHO, in 2013, there were around 9 million new TB cases and close to 1.5 million TB deaths worldwide.
The global tuberculosis testing market has been categorized into seven segments based on major TB test types - smear microscopy, culture based tests, nucleic acid testing, Mantoux test, radiography (chest x-ray), drug susceptibility testing, and other tests such as serological tests, Interferon-Gamma Release Assays (IGRA), phage based tests, antigen-based tests, antibody-based tests, etc. Among such TB testing procedures available, culture based tests was the largest contributor in the global TB testing market. Culture based TB tests include both solid as well as liquid culture tests that have been most widely accepted due to their relatively high specificity and accuracy than other TB tests available in the global market. However, other TB tests segment that includes IGRA, serological tests, and others is expected to register fastest growth during the forecast period from 2014 to 2020 due to many advantages such as fast result generation, high accuracy, requirement of single visit ,etc
The global tuberculosis testing market was valued at USD 1,936.1 million in 2013 and is expected to reach USD 2,619.4 million by 2020, growing at a CAGR of 4.3% from 2014 to 2020. Some of the major driving factors facilitating the growth of this market are increasing incidences of tuberculosis and the rising acceptance of new, innovative, and advanced molecular and rapid culture diagnostic tests worldwide. In addition, increased involvement of some of the world's leading non-profit healthcare organizations for the development of new TB diagnostic tests would further boost the growth this market. Moreover, the TB diagnostics market is observed to be a propelling as many new product developers and manufacturers are expected to venture into the market with a robust pipeline of testing technologies.
Request for Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2267
Asia Pacific dominated the global tuberculosis testing market in 2013 followed by North America. Key factor responsible for Asia Pacific dominating the global TB testing market is the presence of a vast patient pool, which is growing at a rapid pace due to very high incidence rate of the disease, especially in some of the emerging economies of the region, such as India and China. In contrast, North America has a relatively smaller patient pool with lower disease incidences. However, higher awareness, well developed healthcare infrastructure, rapid acceptance of improved but expensive TB tests and better purchasing power are contributing towards the second highest market share of North America.
Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche, Ltd., Hain Lifescience GmbH, bioMérieux SA, Hologic, Inc. QIAGEN, Akonni Biosystems, Inc., Abbott Laboratories, Alere, Inc., Cepheid, Epistem, Plc. and Sanofi are some of the major players operating in the global tuberculosis testing market. Among these, Becton, Dickinson and Company, Thermo Fisher Scientific, Inc, F. Hoffmann-La Roche Ltd. and Hain Lifescience GmbH are the leading players in this market aspiring to introduce novel TB testing technologies in the global market.
Mr. Sudip S
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453